Epigenetic regulation of epithelial-mesenchymal transition by hypoxia in cancer: Targets and therapy

Current Pharmaceutical Design

Volumn 21, Issue 10, 2015, Pages 1272-1278

  Wang, Jian Qiu ^a   Wu, Kou Juey ^b  

^a HANGZHOU NORMAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chromatin modifier; Co regulator; Epigenetic regulation; Epithelial mesenchymal transition; HIF 1 ; Hypoxia; Target

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME; HISTONE; HISTONE MODIFYING ENZYME; TRANSCRIPTIONAL CO REGULATOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CELL HYPOXIA; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; ANIMAL; GENE TARGETING; GENE THERAPY; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE TARGETING; GENETIC THERAPY; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84926341492     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666141211145610     Document Type: Article

References (88)

1. Eccleston A, Cesari F, Skipper M. Transcription and epigenetics. Nature 2013; 502(7472): 461.
2. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 2014.
3. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40(2): 294-309.
4. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148(3): 399-408.
5. Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer-and metastasis-initiating cells. J Cellular Mole Med 2013; 17(1): 30-54.
6. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92(12): 5510-4.
7. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3(10): 721-32.
8. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxiainducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95(14): 7987-92.
9. Corn PG, McDonald ER, 3rd, Herman JG, El-Deiry WS. Tatbinding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genetics 2003; 35(3): 229-37.
10. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxiainducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2(7): 423-7.
11. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13(2): 97-110.
12. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental Cell 2008; 14(6): 818-29.
13. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139(5): 871-90.
14. Liu M, Liu YZ, Feng Y, et al. Novel evidence demonstrates that epithelial-mesenchymal transition contributes to nephrolithiasisinduced renal fibrosis. J Surgical Res 2013; 182(1): 146-52.
15. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mole Cell Biol 2014; 15(3): 178-96.
16. Yang MH, Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle 2008; 7(14): 2090-6.
17. Lundgren K, Nordenskjold B, Landberg G. Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br J Cancer 2009; 101(10): 1769-81.
18. Wu CY, Tsai YP, Wu MZ, Teng SC, Wu KJ. Epigenetic reprogramming and post-transcriptional regulation during the epithelialmesenchymal transition. Trends in genetics : TIG 2012; 28: 454-63.
19. Zhang Q, Bai X, Chen W, et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 2013; 34(5): 962-73.
20. Kiesslich T, Pichler M, Neureiter D. Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol 2013; 1(1): 3-11.
21. Cohen I, Poreba E, Kamieniarz K, Schneider R. Histone modifiers in cancer: friends or foes? Genes Cancer 2011; 2(6): 631-47.
22. Zhang H, Gao L, Anandhakumar J, Gross DS. Uncoupling transcription from covalent histone modification. PLoS Genet 2014; 10(4): e1004202.
23. Bueno MT, Richard S. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase. Epigenetics : official J DNA Methylation Soc 2013; 8(11): 1162-75.
24. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Ann Rev Biochem 2007; 76: 75-100.
25. Gray SG, Teh BT. Histone acetylation/deacetylation and cancer: an "open" and "shut" case? Curr Mol Med 2001; 1(4): 401-29.
26. Sarris M, Nikolaou K, Talianidis I. Context-specific regulation of cancer epigenomes by histone and transcription factor methylation. Oncogene 2014; 33(10): 1207-17.
27. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128(4): 707-19.
28. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genomescale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Structural Mol Biol 2011; 18(8): 867-74.
29. Wu MZ, Tsai YP, Yang MH, et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell 2011; 43(5): 811-22.
30. Xhemalce B, Kouzarides T. A chromodomain switch mediated by histone H3 Lys 4 acetylation regulates heterochromatin assembly. Genes Development 2010; 24(7): 647-52.
31. Karagianni P, Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 2007; 26(37): 5439-49.
32. Wysocka J, Swigut T, Milne TA, et al. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 2005; 121(6): 859-72.
33. Wang YY, Liu LJ, Zhong B, et al. WDR5 is essential for assembly of the VISA-associated signaling complex and virus-triggered IRF3 and NF-kappaB activation. Proc Natl Acad Sci USA 2010; 107(2): 815-20.
34. Ang YS, Tsai SY, Lee DF, et al. Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. Cell 2011; 145(2): 183-97.
35. Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009; 138(5): 1019-31.
36. Kim T, Buratowski S. Dimethylation of H3K4 by Set1 recruits the Set3 histone deacetylase complex to 5' transcribed regions. Cell 2009; 137(2): 259-72.
37. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125(2): 315-26.
38. Chaffer CL, Marjanovic ND, Lee T, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154(1): 61-74.
39. Jiang H, Shukla A, Wang X, Chen WY, Bernstein BE, Roeder RG. Role for Dpy-30 in ES cell-fate specification by regulation of H3K4 methylation within bivalent domains. Cell 2011; 144(4): 513-25.
40. Tsai Y-P, Wu K-J. Epigenetic regulation of hypoxia-responsive gene expression: focusing on chromatin and DNA modifications. Int J Cancer 2014; 134: 249-56.
41. Arzumanyan A, Friedman T, Kotei E, Ng IO, Lian Z, Feitelson MA. Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 2012; 31(5): 563-72.
42. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 2007; 25(1): 15-30.
43. Guillemette B, Drogaris P, Lin HH, et al. H3 lysine 4 is acetylated at active gene promoters and is regulated by H3 lysine 4 methylation. PLoS Genet 2011; 7(3): e1001354.
44. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87(5): 953-9.
45. Ruas JL, Poellinger L, Pereira T. Role of CBP in regulating HIF-1-mediated activation of transcription. J Cell Sci 2005; 118(Pt 2): 301-11.
46. Partch CL, Gardner KH. Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B. Proc Natl Acad Sci USA 2011; 108(19): 7739-44.
47. Sterner DE, Berger SL. Acetylation of histones and transcriptionrelated factors. Microbiology and molecular biology reviews : MMBR 2000; 64(2): 435-59.
48. Wu D, Zhau HE, Huang WC, et al. cAMP-responsive elementbinding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 2007; 26(35): 5070-7.
49. Xu J, Wang R, Xie ZH, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. The Prostate 2006; 66(15): 1664-73.
50. Xenaki G, Ontikatze T, Rajendran R, et al. PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene 2008; 27(44): 5785-96.
51. Jung SY, Malovannaya A, Wei J, O'Malley BW, Qin J. Proteomic analysis of steady-state nuclear hormone receptor coactivator complexes. Mol Endocrinol 2005; 19(10): 2451-65.
52. Privalsky ML, Lee S, Hahm JB, Young BM, Fong RN, Chan IH. The p160 coactivator PAS-B motif stabilizes nuclear receptor binding and contributes to isoform-specific regulation by thyroid hormone receptors. J Biological Chem 2009; 284(29): 19554-63.
53. Koh SS, Chen D, Lee YH, Stallcup MR. Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biological Chem 2001; 276(2): 1089-98.
54. Kasper LH, Boussouar F, Boyd K, et al. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J 2005; 24(22): 3846-58.
55. Chen H, Yan Y, Davidson TL, Shinkai Y, Costa M. Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res 2006; 66(18): 9009-16.
56. Lee JS, Kim Y, Kim IS, et al. Negative regulation of hypoxic responses via induced Reptin methylation. Mol Cell 2010; 39(1): 71-85.
57. Lee JS, Kim Y, Bhin J, et al. Hypoxia-induced methylation of a pontin chromatin remodeling factor. Proc Natl Acad Sci USA 2011; 108(33): 13510-5.
58. Heddleston JM, Wu Q, Rivera M, et al. Hypoxia-induced mixedlineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differentiation 2012; 19(3): 428-39.
59. Lin T, Ponn A, Hu X, Law BK, Lu J. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene 2010; 29(35): 4896-904.
60. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119(7): 941-53.
61. Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Molecular and cellular biology 2010; 30(1): 344-53.
62. Fu L, Chen L, Yang J, Ye T, Chen Y, Fang J. HIF-1alpha-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. Carcinogenesis 2012; 33(9): 1664-73.
63. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci USA 2012; 109(49): E3367-76.
64. Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nature reviews Drug discovery 2013; 12(12): 917-30.
65. Kim JG, Yi JM, Park SJ, et al. Histone demethylase JMJD2Bmediated cell proliferation regulated by hypoxia and radiation in gastric cancer cell. Biochimica et Biophysica acta 2012; 1819(11-12): 1200-7.
66. Yang F, Sun L, Li Q, et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J 2012; 31(1): 110-23.
67. Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98(3): 604-10.
68. Fritzsche FR, Weichert W, Roske A, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC cancer 2008; 8: 381.
69. Krusche CA, Wulfing P, Kersting C, et al. Histone deacetylase-1 and-3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treatment 2005; 90(1): 15-23.
70. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discovery 2007; 6(1): 21-2.
71. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70(3): 273-86.
72. Di Fazio P, Schneider-Stock R, Neureiter D, et al. The pandeacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cellular oncology : the official J Int Soc Cellular Oncol 2010; 32(4): 285-300.
73. Pierce RJ, Dubois-Abdesselem F, Lancelot J, Andrade L, Oliveira G. Targeting schistosome histone modifying enzymes for drug development. Curr Pharm Des 2012; 18(24): 3567-78.
74. Valente S, Mai A. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011-2013). Expert Opinion Therapeutic Patents 2014; 24(4): 401-15.
75. Abaza MS, Bahman AM, Al-Attiyah R. Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells. Int J Oncol 2014; 44(1): 105-28.
76. Mateen S, Raina K, Agarwal C, Chan D, Agarwal R. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Therapeutics 2013; 345(2): 206-14.
77. Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discov Today 2009; 14(19-20): 942-8.
78. Bowers EM, Yan G, Mukherjee C, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 2010; 17(5): 471-82.
79. Yang H, Pinello CE, Luo J, et al. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Mol Cancer Therapeutics 2013; 12(5): 610-20.
80. Liu F, Barsyte-Lovejoy D, Allali-Hassani A, et al. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. J Med Chem 2011; 54(17): 6139-50.
81. Feng T, Wang H, Zhang X, Sun H, You Q. The Discovery of Novel Histone Lysine Methyltransferase G9a Inhibitors (Part 1): Molecular Design Based on a Series of Substituted 2, 4-Diamino-7-aminoalkoxyquinazoline by Molecular-Docking-Guided 3D Quantitative Structure-Activity Relationship Studies. Med Chem 2014; 10(4): 426-40.
82. Lee HT, Choi MR, Doh MS, Jung KH, Chai YG. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Reports 2013; 30(4): 1587-92.
83. Mimasu S, Umezawa N, Sato S, Higuchi T, Umehara T, Yokoyama S. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 2010; 49(30): 6494-503.
84. Hamada S, Suzuki T, Mino K, et al. Design, synthesis, enzymeinhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. J Med Chem 2010; 53(15): 5629-38.
85. King ON, Li XS, Sakurai M, et al. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PloS one 2010; 5(11): e15535.
86. Wang L, Chang J, Varghese D, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Communications 2013; 4: 2035.
87. Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA 2013; 110(19): 7922-7.
88. Knutson SK, Kawano S, Minoshima Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Therapeutics 2014; 13(4): 842-54.